Section 1045 Rollover: QSBS Tacking on Early Founder Sales

Section 1045 exists for one specific scenario: a taxpayer holds qualified small business stock, is forced or chooses to sell before the 5-year section 1202 holding period is met, and wants to preserve QSBS treatment by rolling into a new qualifying issuer. The mechanics are statutorily defined and procedurally narrow. The taxpayer sells. The proceeds are reinvested in replacement QSBS within 60 calendar days. The original holding period tacks onto the replacement stock. The deferred gain reduces basis in the replacement stock. When the replacement stock is eventually sold — after the cumulative holding period reaches 5 years — the section 1202 exclusion applies against the full gain, including the originally deferred amount.

This is the single most important rescue provision in the QSBS toolkit. Without it, a founder forced to sell at year 3 has two choices: pay 23.8% federal tax on the gain (long-term capital gains plus the 3.8% net investment income tax under IRC section 1411) or hold the cash and forfeit any QSBS treatment. Section 1045 creates a third path that preserves the original holding period's economic value.

The 60-day window: the procedural constraint

IRC section 1045(a) requires that the taxpayer purchase replacement QSBS within 60 days of the sale of the original QSBS. The 60 days is measured from the date of sale (typically the closing date of the original transaction), runs in calendar days (not business days), and is non-extendable. There is no hardship waiver, no IRS discretion, and no equitable exception. Missing the window forfeits the rollover entirely — the gain is recognized in full in the year of sale.

For founders contemplating section 1045 as a rescue strategy, the practical implication is that the replacement target must be identified before the original sale closes. Due diligence, term-sheet negotiation, subscription documents, and the actual capital infusion into the replacement company all need to occur within 60 days. For early-stage replacement targets, this is usually feasible. For later-stage replacement targets — particularly those raising priced rounds with extensive diligence requirements — 60 days is tight. Practitioners often advise founders to maintain a pipeline of pre-vetted replacement opportunities so that the 60-day window can be met without rushed diligence.

The tacking rule: why this matters

The structural feature that makes section 1045 valuable is the holding-period tacking rule under IRC section 1045(b)(4). The replacement stock inherits the holding period of the sold stock. If the original QSBS was held 3 years before the forced sale, the replacement QSBS effectively starts at year 3 of the 5-year clock — only 2 additional years of holding are required to reach the section 1202 threshold.

Without tacking, a founder rolling into replacement QSBS at year 3 would face a fresh 5-year holding period starting from the rollover purchase date. Total time to QSBS eligibility on the gain: 8 years from original investment (3 years on original + 5 years on replacement). Tacking compresses this to 5 years total. For a founder whose realistic exit horizon is 6 to 10 years from original investment, the difference is the difference between getting the exclusion and never reaching it.

Basis reduction and the 10x alternative interaction

Section 1045(b)(3) requires that the deferred gain reduce the basis in the replacement QSBS. If a taxpayer sells $5 million of QSBS with $4.5 million of gain (basis $500,000) and reinvests the full $5 million in replacement QSBS, the basis in the replacement stock is $500,000 — the purchase price ($5M) minus the deferred gain ($4.5M).

This basis reduction has two downstream effects. First, when the replacement stock is eventually sold, the gain is calculated against the reduced basis. If the replacement stock appreciates to $8 million at the eventual sale, the gain is $7.5 million ($8M − $500K basis), not the $3 million of post-rollover appreciation alone. The section 1202 exclusion applies against this full $7.5 million gain (subject to the per-issuer $10M or 10x basis cap on the replacement issuer).

Second, the reduced basis affects the 10x basis alternative under section 1202(b)(1)(B). The replacement issuer's per-issuer cap is the greater of $10 million or 10 times the basis in the replacement stock. With the deferred gain reducing basis, the 10x alternative is calculated from the smaller post-rollover basis. In the example above, the 10x cap on the replacement issuer is $5 million (10 × $500K) — less than the standard $10 million default. The taxpayer gets the larger $10 million default cap, but the 10x alternative is diminished by the rollover.

What qualifies as "replacement QSBS"

The replacement stock must independently satisfy every section 1202 requirement as of the date of the rollover purchase:

• Domestic C-corporation: The replacement issuer must be a domestic C-corp at the time of the taxpayer's acquisition. LLCs, S-corps, and foreign entities do not qualify.
• $50 million gross-asset test: The replacement issuer's aggregate gross assets must not exceed $50 million at the time of the rollover purchase, measured under section 1202(d). Companies that have already crossed the $50 million threshold can never issue replacement QSBS.
• Active qualified trade or business: The replacement issuer must conduct an active qualified trade or business under section 1202(e). Excluded industries — health, law, accounting, consulting, financial services, banking, insurance, farming, hospitality, and others enumerated in section 1202(e)(3) — disqualify the rollover.
• Original issuance: The replacement stock must be acquired at original issuance from the replacement issuer, in exchange for money, property (other than stock), or services. Purchasing replacement QSBS on the secondary market does not qualify under section 1045.

The practical consequence: the founder is rolling into a primary investment in a qualifying early-stage company. Buying secondary stock in a private mid-stage company does not satisfy the original-issuance requirement and forfeits the rollover.

Worked example: Austin SaaS founder, year-3 forced exit

An Austin SaaS founder incorporated DataMesh Inc. as a Delaware C-corp in February 2023. She invested $250,000 in cash at original issuance, received 5 million shares, and filed a timely 83(b) election establishing $250,000 basis. The company raised a $4 million seed round and a $12 million Series A; gross assets peaked at $14 million. The company has roughly $7 million in annual recurring revenue and 35 employees in late 2025.

In March 2026 — year 3 of her stock ownership — a strategic acquirer offers $24 million for the company. Her 50% fully-diluted stake yields $12 million in proceeds. She has held her QSBS for 3 years and 1 month. The section 1202 5-year holding period is not yet met. Without section 1045, the entire gain is taxable.

Scenario A: take the cash, pay the tax

• Proceeds: $12,000,000
• Basis: $250,000
• Gain: $11,750,000
• Federal tax at 23.8% (20% LTCG + 3.8% NIIT): $2,796,500
• After-tax cash: $9,203,500

Scenario B: section 1045 rollover into replacement QSBS

The founder identifies a replacement target — InferLab Inc., an early-stage AI infrastructure company structured as a Delaware C-corp with $6 million in gross assets at the time of her investment. She closes the DataMesh sale on March 15, 2026, and on April 30, 2026 (46 days later, within the 60-day window), she invests $12 million into InferLab's Series A round at a $50 million pre-money valuation. The 60-day window is satisfied. The replacement issuer qualifies under section 1202.

• Original QSBS gain deferred under section 1045: $11,750,000
• Basis in replacement (InferLab) stock: $12,000,000 − $11,750,000 deferred gain = $250,000
• Holding period tacked: 3 years and 1 month from DataMesh tacks onto InferLab stock
• Time to 5-year section 1202 threshold on InferLab: 1 year, 11 months remaining

Federal tax in year of sale (2026): $0. The gain is deferred.

Scenario B continued: InferLab exit in May 2028 at $28M

In May 2028, InferLab is acquired for $200 million. The founder's pro-rata stake (assume 14% post-Series A) yields $28 million. She has held InferLab stock for 2 years and 1 month — but with the 3-year tacked period from DataMesh, her cumulative QSBS holding is 5 years and 2 months. The section 1202 5-year threshold is met.

• Proceeds: $28,000,000
• Basis: $250,000 (post-rollover)
• Total gain: $27,750,000
• Section 1202 exclusion (greater of $10M or 10 × $250K = $2.5M): $10,000,000
• Taxable gain: $17,750,000
• Federal tax at 23.8%: $4,224,500
• After-tax cash from InferLab: $23,775,500

Cumulative comparison

• Scenario A (take cash, pay tax, do nothing with proceeds): After-tax from DataMesh = $9,203,500. Subsequent investments not modeled.
• Scenario B (rollover into InferLab, eventual exit): $0 federal tax in 2026, $4,224,500 federal tax in 2028, $23,775,500 after-tax from InferLab in 2028, plus the upside from the InferLab investment growing from $12M to $28M. Combined gain: $27.75M, federal tax: $4.22M, effective rate: 15.2%.

The section 1045 rollover converted a 23.8% effective rate on the original gain into a 15.2% effective rate on the combined gain — saving the founder roughly $2.5 million of federal tax on the original $11.75M of gain, while preserving full exposure to the upside of the InferLab investment.

When section 1045 is the wrong call

The rollover is not always the right answer. Several scenarios make it inferior to taking the cash and paying the tax:

• The founder needs liquidity. Section 1045 reinvests the proceeds — there is no cash left over. A founder who needs the cash to buy a house, pay alimony, fund education, or simply diversify their net worth cannot use 1045 for the full proceeds. Partial rollovers are permitted (the deferred gain is allocated proportionally to the amount reinvested), but the unreinvested portion is fully taxable.
• The replacement target is high risk. The rollover converts liquid cash into illiquid early-stage equity. If the replacement company fails, the original gain is still taxable when the replacement stock becomes worthless (capital loss treatment applies but does not refund the embedded gain on the original QSBS). A failed rollover compounds the loss.
• The founder will become a non-US resident. US-resident taxpayers can use section 1045. Non-resident aliens generally cannot rely on it because section 1202 exclusion treatment depends on US-resident filing status at the time of the eventual sale. A founder planning international relocation should not roll proceeds that will eventually be realized after the residency change.
• State conformity is unfavorable. California does not conform to section 1202 — meaning even after a successful 1045 rollover and 5-year tacked holding period, California state tax applies to the full gain at up to 13.3%. The federal benefit is preserved but the state cost is unchanged. For California-resident founders facing California-resident exits, pre-rollover residency planning is essential.
• The replacement company will not reach a liquidity event. A rollover into a company that never exits is functionally equivalent to a permanent deferral with downside risk. The deferred gain remains embedded in the basis-reduced stock indefinitely.

The election mechanics: how to actually file

Section 1045 is an elective provision — the taxpayer chooses to apply it. The election is made by filing a statement with the taxpayer's timely-filed federal return for the year of the original QSBS sale (including extensions). The statement must include:

• The date of the original QSBS sale and the amount realized
• The taxpayer's basis in the original QSBS
• The realized gain
• The date of the replacement QSBS purchase and the amount paid
• The name, address, and EIN of the replacement issuer
• A representation that the replacement stock qualifies as QSBS under section 1202
• The amount of gain being deferred under section 1045

The election is irrevocable once made for the relevant tax year. Practitioners typically attach a Schedule D entry showing the original sale and a section 1045 deferral statement to the return. The basis reduction in the replacement stock should be tracked on the taxpayer's permanent records — the IRS does not maintain QSBS basis tracking on the taxpayer's behalf, and the taxpayer (and their CPA at the eventual sale) must reconstruct basis from the original documentation.

Interaction with section 1202 stacking strategies

For founders pursuing a multi-company QSBS stacking strategy, section 1045 is the bridge between sequential exits when the holding period on the outgoing company has not yet expired. A founder who exits Company A at year 3, rolls into Company B's Series A under section 1045, and eventually exits Company B at year 5 of the tacked holding period gets:

• $10 million section 1202 exclusion on the cumulative Company A + Company B gain (using the Company B per-issuer cap)
• Holding-period continuity preserved across the rollover
• Full upside on the post-rollover appreciation in Company B

The rollover does not multiply exclusions — the original $10 million cap available on Company A is consumed (or, rather, converted into the Company B cap). For pure stacking benefit (multiple separate exclusions), each company must independently be held for 5 years from its own original-issuance date. But for compressed timelines where individual holding periods are compressed below 5 years, section 1045 preserves exclusion eligibility that would otherwise be forfeited.

What changed under the Inflation Reduction Act and recent guidance

Section 1045 has been on the books since 1997 and has not been substantively amended. Recent regulatory and legislative attention has focused on section 1202 itself (the underlying QSBS exclusion) rather than the 1045 rollover mechanism. The 100% exclusion for QSBS acquired after September 27, 2010 (under section 1202(a)(4)) flows through to rollovers — meaning the replacement QSBS acquired today, if held the full tacked period, qualifies for the 100% federal exclusion at eventual sale.

Proposed legislation in 2024 and 2025 to modify the section 1202 cap (raising or lowering the $10 million threshold) would directly affect the value of section 1045 rollovers, because the rollover ultimately resolves through the section 1202 exclusion at the replacement issuer level. As of 2026-05-22, no enacted legislation has changed the basic mechanics.

Key takeaways

• Section 1045 lets a taxpayer who sells QSBS held more than 6 months but less than 5 years defer the gain by reinvesting in replacement QSBS within 60 days. The deferred gain reduces basis in the replacement stock, and the original holding period tacks onto the replacement stock.
• The 60-day window is non-extendable. Identify replacement targets before the original sale closes — due diligence, term-sheet negotiation, and closing on the replacement stock all must occur within 60 calendar days.
• The replacement issuer must independently qualify under section 1202: domestic C-corporation, gross assets under $50 million at the time of the rollover purchase, active qualified trade or business, original issuance to the taxpayer.
• The tacking rule under section 1045(b)(4) is the structural feature that makes the rollover valuable. A founder who sells QSBS at year 3 and rolls into replacement QSBS needs only 2 additional years of holding to reach the section 1202 5-year threshold.
• The deferred gain reduces basis in the replacement stock and shrinks the 10x basis alternative under section 1202(b)(1)(B). The $10 million default cap remains available, but high-basis founders relying on the 10x alternative may lose some exclusion capacity.
• Section 1045 is the wrong call when the founder needs liquidity, when the replacement target carries high risk of failure, when the founder will become a non-US resident, or when state nonconformity (California, Pennsylvania, others) eliminates much of the benefit.
• The election is made on the timely-filed return for the year of the original sale by attaching a section 1045 statement. The election is irrevocable for that tax year. Basis tracking in the replacement stock is the taxpayer's responsibility — the IRS does not maintain it.